EP2545920A1 - Therapie für Diabeteskomplikationen - Google Patents

Therapie für Diabeteskomplikationen Download PDF

Info

Publication number
EP2545920A1
EP2545920A1 EP12182366A EP12182366A EP2545920A1 EP 2545920 A1 EP2545920 A1 EP 2545920A1 EP 12182366 A EP12182366 A EP 12182366A EP 12182366 A EP12182366 A EP 12182366A EP 2545920 A1 EP2545920 A1 EP 2545920A1
Authority
EP
European Patent Office
Prior art keywords
selective
receptor antagonist
receptor
darusentan
paragraph
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12182366A
Other languages
English (en)
French (fr)
Inventor
Robert L. Roden
Richard J. Gorczynski
Michael J. Gerber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Deutschland GmbH and Co KG
Original Assignee
Abbott GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott GmbH and Co KG filed Critical Abbott GmbH and Co KG
Publication of EP2545920A1 publication Critical patent/EP2545920A1/de
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the present invention relates to selective ET A receptor antagonists and therapeutic combinations useful for improving clinical outcomes in diabetic patients having complications of diabetes such as diabetic nephropathy and/or metabolic syndrome.
  • Hyperglycemia in diabetes mellitus if not controlled, over time causes certain irreversible morphologic changes including glomerular fibrosis in kidneys of affected subjects, a condition known as diabetic nephropathy that is associated with decline in renal function, eventually leading to end-stage renal disease.
  • type 1 diabetes insulin-dependent
  • type 2 diabetes non-insulin-dependent
  • insulin alone may be ineffective in preventing hyperglycemia.
  • insulin sensitivity can be partially or completely lost.
  • Insulin resistance, or loss of insulin sensitivity is one of an array of physiological changes that occur in some individuals who are both obese and diabetic; such physiological changes are collectively known as metabolic syndrome.
  • Diabetic nephropathy and metabolic syndrome are serious complications of diabetes that can dramatically reduce quality of life and survival time. A feature of both these complications is arterial hypertension, which superimposes risk of serious cardiac adverse events on the already high risk of chronic kidney failure arising from these complications.
  • ETs Endothelins
  • ET-1 Endothelins
  • Metabolic syndrome (sometimes referred to as "syndrome X") is characterized by coexistence of glucose intolerance, hypertension, dyslipidemia (specifically elevated LDL (low density lipoprotein) cholesterol and triglycerides and reduced HDL (high density lipoprotein) cholesterol), obesity and susceptibility to cardiovascular disease; these effects are thought to involve a common mechanism in which insulin resistance plays an important part.
  • microalbuminuria the appearance of low but abnormal levels ( ⁇ 30 mg/day) of albumin in the urine. This early stage in development of the disease is known as incipient diabetic nephropathy. Without intervention, about 80% of subjects with type 1 diabetes who develop sustained microalbuminuria exhibit a progressive increase in urinary albumin, eventually (typically after 10-15 years) reaching clinical albuminuria ( ⁇ 300 mg/day), a stage known as overt diabetic nephropathy. Accompanying the increase in albumin excretion is development of arterial hypertension.
  • GFR glomerular filtration rate
  • Avosentan which may be classified as a selective ET A or dual ET A /ET B receptor antagonist, has been reported to be in Phase III clinical development for diabetic nephropathy. See Battistini et al. (2006) Exp. Biol. Med. 231:653-695 .
  • BSF 208075 (said to be a selective ET A receptor antagonist) reduced plasma glucose levels and improved plasma glucose clearance rates in hyperglycemic rats.
  • ET-1 antagonists may function as effectively as selective ETN A blockers.
  • a need was proposed for prospective trials to assess whether ET-1 antagonists, either alone or in combination, are superior to other more conventional treatments such as insulin sensitizers and to evaluate effects of combined therapies on development of insulin resistance and progression of diabetes.
  • Subjects having diabetic nephropathy and/or metabolic syndrome represent a particularly challenging subpopulation of diabetic patients, for whom therapies giving improved outcomes with respect to quality of life and survival time, through enhanced glycemic control and/or insulin sensitivity, would represent an important advance in the art.
  • an even more challenging patient population comprises subjects having at least one of these complications of diabetes and exhibiting inadequate blood pressure control by standard antihypertensive therapies.
  • Subjects exhibiting resistance to a baseline antihypertensive therapy with one or more drugs include patients having clinically diagnosed resistant hypertension. Resistant hypertension is defined by the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7; Chobanian et al.
  • Hypertension 42:1206-1252 as a failure to achieve goal blood pressure in patients who are adhering to full doses of an appropriate three-drug regimen that includes a diuretic. Further, resistant hypertension is diagnosed by many physicians on the basis of a patient's resistance to adequate, but less than full, doses of an appropriate three-drug regimen because of the risk or occurrence of adverse events associated with full doses.
  • the terms "adequate” and “full” in the present context are defined hereinbelow.
  • JNC 7 recommends a goal of systolic blood pressure (SBP) ⁇ 130 mmHg and diastolic blood pressure (DBP) ⁇ 80 mmHg.
  • SBP systolic blood pressure
  • DBP diastolic blood pressure
  • JNC 7 recommends a goal of systolic blood pressure (SBP) ⁇ 130 mmHg and diastolic blood pressure (DBP) ⁇ 80 mmHg.
  • SBP systolic blood pressure
  • DBP diastolic blood pressure
  • German Patent No. DE 19744799 of Knoll mentions, in the abstract thereof, combinations of an endothelin antagonist, such as darusentan, and a diuretic said to show synergistic activity in treatment of hypertension, coronary artery disease, cardiac or renal insufficiency, renal or myocardial ischemia, subarachnoid hemorrhage, Raynaud's disease and peripheral arterial occlusion.
  • an endothelin antagonist such as darusentan
  • a diuretic said to show synergistic activity in treatment of hypertension, coronary artery disease, cardiac or renal insufficiency, renal or myocardial ischemia, subarachnoid hemorrhage, Raynaud's disease and peripheral arterial occlusion.
  • U.S. Patent No. 6,352,992 to Jagast et al proposes pharmaceutical combination preparations comprising a beta-receptor blocker and an endothelin antagonist for treatment of vasoconstrictive disorders.
  • endothelin antagonists mentioned is darusentan.
  • German Patent No. DE 19743142 of Knoll proposes combinations of an endothelin antagonist, such as darusentan, and a calcium antagonist for treatment of cardiovascular disorders such as pulmonary hypertension and renal and myocardial ischemia.
  • U.S. Patent No. 6,329,384 to Munter et al proposes combinations of endothelin antagonists, such as darusentan, and renin-angiotensin system inhibitors, in particular angiotensin II antagonists and angiotensin converting enzyme (ACE) inhibitors for treatment of vasoconstrictive disorders such as hypertension, heart failure, ischemia or vasospasms.
  • endothelin antagonists such as darusentan
  • renin-angiotensin system inhibitors in particular angiotensin II antagonists and angiotensin converting enzyme (ACE) inhibitors for treatment of vasoconstrictive disorders such as hypertension, heart failure, ischemia or vasospasms.
  • ACE angiotensin converting enzyme
  • German Patent No. DE 19743140 of Knoll proposes combinations of an endothelin antagonist, such as darusentan, and a vasodilator for treatment of cardiovascular disorders such as pulmonary hypertension, renal or myocardial ischemia, subarachnoid hemorrhage, Raynaud's disease, and peripheral arterial occlusion.
  • an endothelin antagonist such as darusentan
  • a vasodilator for treatment of cardiovascular disorders such as pulmonary hypertension, renal or myocardial ischemia, subarachnoid hemorrhage, Raynaud's disease, and peripheral arterial occlusion.
  • a selective ET A receptor antagonist for use in a method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome.
  • a selective ET A receptor antagonist for use in treating a complex of comorbidities in an elderly diabetic human subject, wherein the selective ET A receptor antagonist is for administration in combination or as adjunctive therapy with (a) at least one additional agent that is (i) other than a selective ET A receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension, and optionally (b) at least one antihypertensive other than a selective ET A receptor antagonist.
  • a therapeutic combination comprising a selective ET A receptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ET A receptor antagonist.
  • Fig. 1 is a schematic diagram of the clinical study described in Example 2 herein.
  • diabetes as used herein will be understood to include both incipient and overt stages of diabetic nephropathy, whether diagnosed or not, but most typically as diagnosed by a clinician or physician.
  • metabolic syndrome refers to a complex of obesity, hypertension, dyslipidemia and diabetes marked by a degree of insulin resistance. The existence of metabolic syndrome as a true clinical syndrome is not universally accepted; it will be understood that in the present context a patient having metabolic syndrome is one exhibiting a complex of conditions as itemized above, whether or not "metabolic syndrome" is formally diagnosed in the patient.
  • the method of the invention is "for enhancing glycemic control and/or insulin sensitivity" in a human subject. Where glycemic control is enhanced, such enhancement can, but does not necessarily, arise from increased insulin sensitivity. Likewise, where insulin sensitivity is enhanced, such enhancement can, but does not necessarily, lead to improved glycemic control.
  • practice of the method leads to enhancement of glycemic control, particularly in a subject having diabetic nephropathy and/or metabolic syndrome.
  • practice of the method leads to enhancement of insulin sensitivity, particularly in a subject having diabetic nephropathy and/or metabolic syndrome.
  • Insulin sensitivity may be measured by standard insulin models, such as HOMA-IR (homeostasis model assessment of insulin resistance).
  • practice of the method leads to enhancement in both glycemic control and insulin sensitivity, particularly in a subject having diabetic nephropathy, and/or metabolic syndrome.
  • Enhancement of glycemic control is typically manifested by a reduction in tendency for hyperglycemia.
  • a fasting (e.g ., preprandial) blood glucose level greater than about 140 mg/dl, or a bedtime blood glucose level greater than about 160 mg/dl can be evidence of hyperglycemia.
  • Any reduction in blood glucose level can be beneficial to a subject having hyperglycemia, for example a reduction by at least about 5, at least about 10, at least about 15 or at least about 20 mg/dl.
  • glucose level is brought into a goal range for healthy subjects of about 80 to about 120 mg/dl (preprandial) or about 100 to about 140 mg/dl (bedtime).
  • Reduction of glucose level in urine can also provide evidence of enhanced glycemic control, but is less reliable than blood measurements because excretion of glucose in urine typically does not occur unless blood glucose level exceeds about 180 mg/dl.
  • HbA 1c glycosylated hemoglobin
  • This test reflects blood glucose concentration over a period of time related to the life-span of red blood cells (about 120 days), and consequently is not affected by daily or hourly fluctuations in blood glucose level.
  • a patient having an HbA 1c test result greater than about 8% is normally considered hyperglycemic.
  • Any reduction in HbA 1c level can be beneficial to such a patient, for example a reduction by at least about 0.5, at least about 1, at least about 1.5 or at least about 2 percentage points.
  • HbA 1c level is brought into a goal range for healthy subjects of about 4% to about 6%.
  • Subjects having diabetic nephropathy and/or metabolic syndrome can be of any age, but incidence of these complications of diabetes increases markedly with age. Older subjects can respond differently from younger subjects to treatment, and can have a different spectrum of adverse effects. It is contemplated herein that elderly subjects (i.e ., subjects at least about 50, for example at least about 55, at least about 60 or at least about 65 years old) can benefit especially greatly from treatment according to the present method, in part because of the severity with which their quality of life and survival time are impacted by these complications of diabetes, and in part because the particular adverse side effects that have been noted for ET antagonists, including reproductive effects, are of lesser significance later in life.
  • ET antagonists including reproductive effects
  • the subject has incipient diabetic nephropathy.
  • the subject has overt diabetic nephropathy.
  • the subject has incipient or overt diabetic nephropathy and practice of the method provides a further beneficial effect in one or more morphologic markers of diabetic nephropathy
  • a "morphologic marker" in the present context is any structural or histological feature of the kidney or a tissue thereof, whether observable macroscopically, by light microscopy or by electron microscopy. Such markers can be observable directly, for example by biopsy, or indirectly, through a secondary effect specific to the marker.
  • morphologic markers of diabetic nephropathy include, without limitation, kidney size, kidney weight, GBM thickening, mesangial expansion, deposition of collagen, fibronectin and laminin, nephron density, nodular glomerulosclerosis, atherosclerosis of renal vasculature or a combination thereof.
  • the subject has incipient or overt diabetic nephropathy and practice of the method provides a further beneficial effect in one or more indicators of renal function, for example GFR, creatinine clearance, albuminuria or a combination thereof.
  • indicators of renal function for example GFR, creatinine clearance, albuminuria or a combination thereof.
  • a "beneficial effect" of the present method can take the form of an improvement over baseline, i.e ., an improvement over a measurement or observation made prior to initiation of therapy according to the method. For example, a reduction in amount of collagen deposited, an increase in GFR (in a subject having overt diabetic nephropathy) or a reduction in albuminuria by comparison with a baseline level would represent such an improvement.
  • a "beneficial effect” can also take the form of an arresting, slowing, retarding or stabilizing of a deleterious progression in any of the above markers or functional effects of diabetic nephropathy. For example, even if GFR is not increased or albuminuria is not reduced by comparison with baseline measurements, a reduction in the rate of decrease of GFR or the rate of increase of albuminuria would represent a beneficial effect of the present method.
  • practice of the invention leads to an arresting, slowing, retarding or stabilizing of the progression of diabetic nephropathy in the subject.
  • Such arresting, slowing, retarding or stabilizing of progression of the disease can result in extension of the time to end-stage renal disease or chronic kidney failure, which in turn can extend survival time of the subject.
  • a selective ET A receptor antagonist useful herein exhibits an affinity (as expressed by dissociation constant K i ) for ET A not greater than about 10 nM and a selectivity for ET A over ET B (as expressed by the ratio K i (ET B )/K i (ET A )) of at least about 50.
  • K i (ET A ) is not greater than about 5 nM, not greater than about 2 nM, not greater than about 1 nM, not greater than about 0.5 nM or not greater than about 0.2 nM.
  • K i (ET B )/K i (ET A ) is at least about 100, at least about 200, at least about 500 or at least about 1000.
  • Suitable selective ET A receptor antagonists can be identified by one of ordinary skill from literature on such antagonists, based on the disclosure herein, but a non-limiting list of such antagonists includes ambrisentan, atrasentan, avosentan, BMS 193884, BQ-123, CI-1020, clazosentan, darusentan, edonentan, S-0139, SB-209670, sitaxsentan, TA-0201, tarasentan, TBC 3711, tezosentan, YM-598, ZD-1611 and ZD-4054, as well as salts, esters, prodrugs, metabolites, tautomers, racemates and enantiomers thereof.
  • the selective ET A receptor antagonist comprises darusentan ((+)-(S)-2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-3-methoxy-3,3-diphenylpropionic acid). This compound has the formula
  • 125 [I]-wendothelin-1 preceptor binding cold ligand competition curves were performed in human myocardial membranes prepared from failing and non-failing left ventricles, and cold ligand dissociation constants (K i ) for ET A and ET B preceptors were determined by computer modeling, Assay conditions included 10 ⁇ M Gpp(NH)p (guanylyl-5'-imidodiphosphate) to eliminate high-affinity agonist binding, 18-point competition curves from 1 pM to 100 ⁇ M, and a 4-hour incubation time to achieve steady-state binding.
  • Gpp(NH)p guanylyl-5'-imidodiphosphate
  • the selective ET A receptor antagonist is administered "in a glycemic control and/or insulin sensitivity enhancing effective amount.” What constitutes such an effective amount will depend on the particular selective ET A receptor antagonist used, on the individual subject, on the dosage form and route of administration used and on other factors, and can be readily determined by one of skill in the art without undue experimentation based on the disclosure herein. Any dose that is effective for enhancing glycemic control and/or insulin sensitivity, up to a maximum that is tolerated by the subject without unacceptable adverse side effects, can be administered. Illustratively for darusentan, such a dose is likely to be about 1 to about 600 mg/day, for example about 5 to about 450 mg/day or about 10 to about 300 mg/day. Higher or lower doses can be useful in specific circumstances. Useful doses of other selective ET A receptor antagonists are doses that are therapeutically equivalent to such a dose of darusentan.
  • the desired daily dosage amount can be administered in any suitable number of individual doses, for example four times, three times, twice or once a day.
  • a dosage form having appropriate controlled release properties a lower frequency of administration may be possible, for example once every two days, once a week, etc.
  • the selective ET A receptor antagonist is administered according to a therapeutic regimen wherein dose and frequency of administration and duration of therapy are effective to lower blood glucose level by at least about 10 mg/dl and/or to lower HbA 1c level by at least about 0.5 percentage points,
  • the selective ET A receptor antagonist is administered according to a therapeutic regimen wherein dose and frequency of administration and duration of therapy are effective to achieve a goal preprandial blood glucose level of about 80 to about 120 mg/dl, a goal bedtime blood glucose level of about 100 to about 140 mg/dl and/or a goal HbA 1c level not greater than about 7%.
  • Benefits of the present method may not be evident immediately upon initiating a therapeutic regimen as described herein. In particular, it can take some time for it to become evident that progression of a complication of diabetes such as diabetic neuropathy has been slowed. It is therefore contemplated that administration of a selective ET A receptor antagonist will in some cases continue for an extended period of time, typically at least about 1 month, more typically at least about 3 months. Duration of therapy in some embodiments can be at least about 1 year, at least about 5 years, or for as long as needed, which can be lifelong (i.e., from a time of initiation of treatment for substantially the remainder of the patient's life).
  • duration of therapy is from a time of diagnosis of diabetic nephropathy (whether incipient or overt) at least to a time of progression of the diabetic nephropathy into end-stage renal disease.
  • the method of this embodiment will be successful in preventing progression of the disease to end-stage; in such situations the treatment can be continued indefinitely.
  • administration of the selective ET A receptor antagonist can continue for as long as a therapeutic benefit is provided thereby and any adverse side effects thereof remain commensurate with the therapeutic benefit.
  • Selective ET A receptor antagonists are known to be useful as antihypertensive agents.
  • practice of the present method is likely to provide a benefit not only in glycemic control and/or insulin sensitivity as outlined above, but an additional benefit in lowering blood pressure.
  • hypertension is an important feature of both diabetic nephropathy and metabolic syndrome, these benefits can be mutually reinforcing.
  • Any one or more measures of blood pressure can be lowered by a method as described herein, including SBP and/or DBP as determined, for example, by sphygmomanometry.
  • SBP and/or DBP can be measured, for example, in a sitting or ambulatory patient.
  • a "trough sitting" SBP or DBP is measured at a time point when serum concentration of a drug or drugs administered according to a method of the invention is expected to be at or close to its lowest in a treatment cycle, typically just before administration of a further dose.
  • trough sitting systolic or diastolic blood pressure can be measured at that time, immediately before the daily administration. It is generally preferred to measure trough sitting SBP or DBP at around the same time of day for each such measurement, to minimize variation due to the natural diurnal blood pressure cycle.
  • a "24-hour ambulatory" SBP or DBP is an average of measurements taken repeatedly in the course of a 24-hour period, in an ambulatory patient.
  • a "maximum diurnal" SBP or DBP is a measure of highest SBP or DBP recorded in a 24-hour period, and often reflects the peak of the natural diurnal blood pressure cycle, typically occurring in the morning, for example between about 5 am and about 11 am. Commonly, a second peak occurs in the evening, for example between about 5 pm and 10 pm. Such a bimodal waveform diurnal ABP pattern may be especially characteristic of resistant hypertension.
  • a common feature of resistant hypertension is a nighttime (defined herein as 2200 to 0600) mean systolic ABP that is less than about 10% lower than the daytime (defined herein as 0600 to 2200) mean systolic ABP.
  • the parameter herein termed "day/night ABP ratio" expressed as a percentage is calculated as (daytime mean - nighttime mean)/daytime mean X 100.
  • a diurnal ABP pattern having a day/night ABP ratio of less than about 10% is sometimes referred to as a "non-dipping ABP".
  • the patient receiving therapy according to a method of the invention can be a patient exhibiting resistance to a baseline antihypertensive therapy with one or more drugs.
  • a “baseline antihypertensive therapy” herein means a therapeutic regimen comprising administration of one or more drugs, not including a selective ET A receptor antagonist, with an objective (which can be the primary objective or a secondary objective of the regimen) of lowering blood pressure in the patient.
  • Each drug according to the regimen is administered at least at a dose considered by an attending physician to be adequate for treatment of hypertension, taking into account the particular patient's medical condition and tolerance for the drug without unacceptable adverse side-effects.
  • An "adequate" dose as prescribed by the physician can be less than or equal to a full dose of the drug.
  • a “full” dose is the lowest of (a) the highest dose of the drug labeled for a hypertension indication; (b) the highest usual dose of the drug prescribed according to JNC 7, BHD-IV, ESH/ESC or WHO/ISH guidelines; or (c) the highest tolerated dose of the drug in the particular patient.
  • a baseline antihypertensive therapy illustratively comprises administering one or more diuretics and/or one or more antihypertensive drugs selected from (a) angiotensin converting enzyme inhibitors and angiotensin II receptor blockers, (b) beta-adrenergic receptor blockers, (c) calcium channel blockers, (d) direct vasodilators, (e) alpha-1-adrenergic receptor blockers, (f) central alpha-2-adrenergic receptor agonists and other centrally acting antihypertensive drugs, and (g) aldosterone receptor antagonists.
  • drugs of still further classes can be included in the baseline therapy.
  • a patient who is "resistant" to a baseline antihypertensive therapy is one in whom hypertension is failing to respond adequately or at all to the baseline therapy.
  • the patient receiving the baseline therapy is failing to reach an established blood pressure goal, as set forth for U.S. patients, for example, in JNC 7 or comparable standards in other countries (e.g., BHD-IV, ESH/ESC or WHO/ISH guidelines).
  • the JNC 7 goal in a patient having a complicating condition such as diabetes and/or chronic kidney disease is ⁇ 130 mmHg SBP and ⁇ 80 mmHg DBP.
  • a clinically meaningful lowering of blood pressure can be obtained in such patients by use of a selective ET A receptor antagonist such as darusentan.
  • a reduction of at least about 3 mmHg in any blood pressure parameter can be considered clinically meaningful.
  • a method for enhancing glycemic control and/or insulin sensitivity and for lowering blood pressure in a patient exhibiting resistance to a baseline antihypertensive therapy comprises administering to the patient a selective ET A receptor antagonist, for example darusentan, at a dose and frequency effective to provide a reduction of at least about 3 mmHg in trough sitting SBP and/or DBP, 24-hour ambulatory SBP and/or DBP, and/or maximum diurnal SBP and/or DBP.
  • a selective ET A receptor antagonist for example darusentan
  • a method for enhancing glycemic control and/or insulin sensitivity and for lowering blood pressure in a patient exhibiting resistance to a baseline antihypertensive therapy with one or more drugs comprises administering darusentan to the patient adjunctively with said one or more drugs.
  • the selective ET A receptor antagonist for example darusentan
  • the selective ET A receptor antagonist can be administered alone, i.e., in monotherapy, it is contemplated that in most cases combination therapy, for example but not necessarily with one or more drugs of the baseline therapy to which the patient has proved resistant, will be desirable.
  • a benefit of the administration of darusentan can be that, at least in some circumstances, it can permit dose reduction, or even elimination, of at least one of the drugs in the baseline therapy.
  • baseline antihypertensive therapy drugs can have undesirable, in some cases clinically unacceptable or even dangerous, adverse side effects.
  • potassium-sparing diuretic drugs can be associated with increased risk of hyperkalemia and related disorders.
  • Overuse of loop diuretics can cause depletion of sodium resulting in hyponatremia and/or extracellular fluid volume depletion associated with hypotension, reduced GFR, circulatory collapse, and thromboembolic episodes.
  • loop diuretics can cause ototoxicity that results in tinnitus, hearing impairment, deafness and/or vertigo.
  • Thiazide diuretics similarly to loop diuretics, can have adverse effects related to abnormalities of fluid and electrolyte balance.
  • Such adverse events include extracellular volume depletion, hypotension, hypokalemia, hyponatremia, hypochloremia, metabolic alkalosis, hypomagnesemia, hypercalcemia and hyperuricemia.
  • Thiazide diuretics can also decrease glucose tolerance, and increase plasma levels of LDL cholesterol, total cholesterol, and total triglycerides.
  • Angiotensin converting enzyme (ACE) inhibitors are associated with cough and increased risk of angioedema.
  • Beta-adrenergic receptor blockers are associated with increased risk of bronchospasm, bradycardia, heart block, excess negative inotropic effect, peripheral arterial insufficiency and sometimes male impotence.
  • Calcium channel blockers are associated with increased risk of lower limb edema. Further information on adverse events associated with antihypertensive drugs can be found, for example, in standard reference works such as Goodman & Gilman's The Pharmaceutical Basis of Therapeutics, 13th ed .
  • Adjunctive administration of darusentan in the present context means that the darusentan is administered concomitantly with a baseline hypertensive therapy as defined above, with or without dose reduction of one or more drugs in the baseline therapy.
  • darusentan can be administered adjunctively with an adequate to full dose of each of the drugs in the baseline therapy.
  • the dose and frequency of darusentan administration is, in one embodiment, effective in combination with the baseline therapy to provide a reduction of at least about 3 mmHg in trough sitting SBP and/or DBP, 24-hour ambulatory SBP and/or DBP, and/or maximum diurnal SBP and/or DBP.
  • a method of the present invention is especially beneficial where the patient has clinically diagnosed resistant hypertension.
  • a patient exhibits resistance to an antihypertensive regimen of at least three drugs including a diuretic.
  • the patient having resistant hypertension exhibits resistance to a baseline antihypertensive therapy that comprises at least the following:
  • the patient is resistant to an even more comprehensive baseline therapy, further comprising, for example, one or more direct vasodilators, alpha-1-adrenergic blockers, central alpha-2-adrenergic agonists or other centrally acting antihypertensive drugs, and/or aldosterone receptor antagonists,
  • the selective ET A receptor antagonist is administered orally
  • the invention is not limited to any route of administration, so long as the route selected results in effective delivery of the drug so that the stated benefits are obtainable.
  • administration of the darusentan can illustratively be parenteral (e.g., intravenous, intraperitoneal, subcutaneous or intradermal), transdermal, transmucosal (e.g., buccal, sublingual or intranasal), intraocular, intrapulmonary (e.g ., by inhalation) or rectal.
  • the selective ET A receptor antagonist is administered orally, i.e., per os (p.o.).
  • Any suitable orally deliverable dosage form can be used for the selective ET A receptor antagonist, including without limitation tablets, capsules (solid- or liquid-filled), powders, granules, syrups and other liquids, etc .
  • the selective ET A receptor antagonist is administered adjunctively with (1) one or more diuretics; and (2) two or more antihypertensive drugs, selected from (a) ACE inhibitors and angiotensin II receptor blockers; (b) beta-adrenergic receptor blockers; and (c) calcium channel blockers.
  • Each of these diuretic and antihypertensive drugs is typically administered at an adequate to full dose.
  • One of skill in the art can readily identify a suitable dose for any particular diuretic or antihypertensive drug from publicly available information in printed or electronic form, for example on the internet.
  • Examples of drugs useful in combination or adjunctive therapy with a selective ET A preceptor antagonist, for example darusentan, or as a component of a baseline antihypertensive therapy are classified and presented in several lists below. Some drugs are active at more than one target; accordingly certain drugs may appear in more than one list. Use of any listed drug in a combination or adjunctive therapy of the invention is contemplated herein, independently of its mode of action.
  • a suitable diuretic can illustratively be selected from the following list:
  • the diuretic if present comprises a thiazide or loop diuretic.
  • Thiazide diuretics are generally not preferred where the patient has a complicating condition such as diabetes or chronic kidney disease, and in such situations a loop diuretic can be a better choice.
  • Particularly suitable thiazide diuretics for example for use with darusentan, include chlorothiazide, chlorthalidone, hydrochlorothiazide, indapamide, metolazone, polythiazide and combinations thereof.
  • Particularly suitable loop diuretics include bumetanide, furosemide, torsemide and combinations thereof.
  • a suitable ACE inhibitor can illustratively be selected from the following list:
  • Particularly suitable ACE inhibitors for example for use with darusentan, include benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril and combinations thereof.
  • a suitable angiotensin II receptor blocker can illustratively be selected from the following list:
  • a suitable beta-adrenergic receptor blocker can illustratively be selected from the following list:
  • beta-adrenergic receptor blockers for example for use with darusentan, include acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, labetalol, metoprolol, nadolol, penbutolol, pindolol, propranolol, timolol and combinations thereof.
  • a suitable calcium channel blocker can illustratively be selected from the following list:
  • Particularly suitable calcium channel blockers for example for use with darusentan, include amlodipine, diltiazem, felodipine, isradipine, nicardipine, nifedipine, nisoldipine, verapamil and combinations thereof.
  • one or more additional antihypertensive drugs can be administered.
  • These can be selected, for example, from direct vasodilators, alpha-1-adrenergic receptor blockers, central alpha-2-adrenergic receptor agonists and other centrally acting antihypertensive drugs, and aldosterone receptor antagonists.
  • a suitable direct vasodilator can illustratively be selected from the following list:
  • Particularly suitable direct vasodilators for example for use with darusentan, include hydralazine, minoxidil and combinations thereof.
  • a suitable alpha-1-adrenergic receptor blocker can illustratively be selected from the following list:
  • alpha-1-adrenergic receptor blockers for example for use with darusentan, include carvedilol, doxazosin, labetalol, prazosin, terazosin and combinations thereof. It is noted that, of these, carvedilol and labetalol also function as beta-adrenergic receptor blockers,
  • a suitable central alpha-2-adrenergic receptor agonist or other centrally acting antihypertensive drug can illustratively be selected from the following list;
  • a suitable aldosterone receptor antagonist can illustratively be selected from the following list:
  • vasopeptidase inhibitors include vasopeptidase inhibitors, NEP (neutral endopeptidase) inhibitors, prostanoids (particularly oral prostanoids), PDE5 (phosphodiesterase type 5) inhibitors, nitrosylated compounds and oral nitrates.
  • NEP neutral endopeptidase
  • prostanoids particularly oral prostanoids
  • PDE5 phosphodiesterase type 5
  • Illustrative vasopeptidase inhibitors include:
  • NEP inhibitors some of which are also ACE inhibitors, include:
  • Illustrative prostanoids include:
  • Illustrative PDE5 inhibitors include:
  • drugs that can be useful in combination or adjunctive therapy with darusentan or in a baseline antihypertensive therapy can illustratively be selected from the following unclassified list:
  • the selective ET A receptor antagonist is administered concomitantly (e.g., in combination or adjunctive therapy) with one or more of
  • the selective ET A receptor antagonist more specifically darusentan
  • the selective ET A receptor antagonist more specifically darusentan, can be administered in combination or adjunctive therapy at least with (a) and any two of (b), (c) and (d).
  • the one or more drugs constituting the baseline antihypertensive therapy and optionally administered in combination with the selective ET A receptor antagonist can be delivered by any suitable route of administration.
  • such drugs are suitable for oral administration, and many are suitable for once a day oral administration.
  • at least one of the diuretic or antihypertensive drugs in the baseline therapy is orally administered once a day.
  • all drugs in the baseline therapy are orally administered once a day. According to this embodiment, it will generally be found convenient to administer all drugs in the regimen, i.e., the selective ET A receptor antagonist as well as the baseline therapy drugs, orally once a day.
  • combination or adjunctive therapies as indicated above while of particular benefit in patients having resistant hypertension, are not limited to such patients.
  • Hypertension is a common feature of most complications of diabetes, including both diabetic nephropathy and metabolic syndrome, and it is contemplated that combination or adjunctive therapies of a selective ET A receptor antagonist with one or more antihypertensive drugs other than selective ET A receptor antagonists can be useful in many diabetic patients having these complications.
  • Another kind of combination or adjunctive therapy that can be useful according to the present invention includes a selective ET A receptor antagonist and one or more additional antidiabetic agents other than selective ET A receptor antagonists.
  • additional antidiabetic agents can, for example, be selected from alpha-glucosidase inhibitors, biguanides, exendins, hormones and analogs thereof, meglitinides, sulfonylurea derivatives and thiazolidinediones.
  • a suitable antidiabetic can illustratively be selected from the following list:
  • Particularly suitable antidiabetics for example for use with darusentan, include acarbose, exenatide, glimepiride, insulins, metformin, nateglinide, pioglitazone, pramlintide, rosiglitazone and combinations thereof.
  • a selective ET A receptor antagonist can be administered in combination or adjunctive therapy with one or more additional agents selected from antidiabetics (for example as listed above), antihypertensives (for example as listed above), anti-obesity agents and antidyslipidemics.
  • Suitable anti-obesity agents include anorexics, CB1 receptor blockers and lipase inhibitors.
  • a suitable anti-obesity agent can illustratively be selected from the following list:
  • anti-obesity agents for example for use with darusentan, include benzphetamine, methamphetamine, orlistat, phendimetrazine, phentermine, rimonabant, sibutramine and combinations thereof.
  • Suitable antidyslipidemics include bile acid sequestrants, cholesterol absorption inhibitors, fibrates, HMG CoA reductase inhibitors (statins), nicotinic acid derivatives, and thyroid hormones and analogs thereof.
  • a suitable antidyslipidemic can illustratively be selected from the following list:
  • antidyslipidemics for example for use with darusentan, include atorvastatin, colesevelam, ezetimibe, fenofibrate, fluvastatin, lovastatin, niacin, rosuvastatin, simvastatin and combinations thereof.
  • the selective ET A receptor antagonist can itself have useful antidyslipidemic activity, for example secondary to its activity in enhancing glycemic control and/or insulin sensitivity.
  • the selective ET A receptor antagonist and at least one additional antidiabetic, antihypertensive, anti-obesity agent and/or antidyslipidemic can be administered at different times or at about the same time (at exactly the same time or directly one after the other in any order).
  • the selective ET A receptor antagonist and the at least one antidiabetic, antihypertensive, anti-obesity agent and/or antidyslipidemic can be formulated in one dosage form as a fixed-dose combination for administration at the same time, or in two or more separate dosage forms for administration at the same or different times.
  • Separate dosage forms can optionally be co-packaged, for example in a single container or in a plurality of containers within a single outer package, or co-presented in separate packaging ("common presentation").
  • a kit is contemplated comprising, in separate containers, darusentan and at least one drug useful in combination or adjunctive therapy with darusentan, for example an antidiabetic, antihypertensive, anti-obesity agent or antidyslipidemic.
  • darusentan and at least one drug useful in combination or adjunctive therapy with darusentan are separately packaged and available for sale independently of one another, but are co-marketed or co-promoted for use according to the invention.
  • the separate dosage forms can also be presented to a patient separately and independently, for use according to the invention.
  • a further embodiment of the present invention provides a method for treating a complex of comorbidities in an elderly diabetic human subject. This method comprises administering to the subject a selective ET A receptor antagonist in combination or adjunctive therapy with
  • a "comorbidity” is a disease condition present in the subject in addition to diabetes, that adds to the deleterious effects of the diabetes on the subject and/or affects the choice of therapy. Comorbidities can arise secondarily from the diabetes or from other comorbidities, or may arise independently. Among comorbidities commonly occurring in an elderly diabetic patient population are, illustratively, insulin resistance, chronic kidney disease, hypertension, dyslipidemia, obesity, cardiac insufficiency and sleep apnea.
  • a “complex" of comorbidities is defined herein as the presence of at least two such comorbidities, in addition to the underlying diabetes.
  • the subject presents with at least three, or even four or more, such comorbidities.
  • a subject can exhibit diabetes with insulin resistance, hypertension, dyslipidemia and obesity.
  • Treating in the present context includes alleviating symptoms, enhancing glycemic control and/or insulin sensitivity, arresting, slowing, retarding or stabilizing progression of a condition or a physiological or morphological marker thereof, and/or improving clinical outcome, for example as measured by quality of life, incidence or severity of adverse cardiac events, time to end-stage renal disease or survival time.
  • the selective ET A receptor antagonist can illustratively be selected from those mentioned hereinabove.
  • the selective ET A receptor antagonist comprises darusentan, for example at dosage amounts and frequencies of administration, by routes of administration and dosage forms, and for duration of treatment as indicated hereinabove.
  • the selective ET A receptor antagonist e.g., darusentan
  • the selective ET A receptor antagonist can contribute in a substantial way to clinical improvement in each of a plurality of comorbidities, for example supplementing the effect of, co-acting with, or permitting dose reduction (with potential benefits in reducing adverse side-effects) in at least one additional agent.
  • the adjunctive or combination therapy of the present embodiment brings great benefit to the elderly diabetic patient by enabling a complex of comorbidities, as seen for example in diabetic nephropathy or metabolic syndrome, to be simultaneously addressed.
  • the at least one additional agent that is (i) other than a selective ET A receptor antagonist and (ii) effective in treatment of diabetes and/or at least one comorbidity other than hypertension can comprise, for example, one or more antidiabetics, anti-obesity agents and/or antidyslipidemics, including any such agents listed hereinabove.
  • one or more agents selected from acarbose, exenatide, glimepiride, insulins, metformin, nateglinide, pioglitazone, pramlintide, rosiglitazone, benzphetamine, methamphetamine, orlistat, phendimetrazine, phentermine, rimonabant, sibutramine, atorvastatin, colesevelam, ezetimibe, fenofibrate, fluvastatin, lovastatin, niacin, rosuvastatin, simvastatin and combinations thereof can be administered in adjunctive or combination therapy with a selective ET A receptor antagonist, for example darusentan.
  • a selective ET A receptor antagonist for example darusentan.
  • Antihypertensive(s) optionally additionally present in the adjunctive or combination therapy can comprise, for example, agents of any class listed hereinabove, including diuretics, ACE inhibitors, angiotensin II receptor blockers, beta-adrenergic receptor blockers, calcium channel blockers, direct vasodilators, alpha-1-adrenergic receptor blockers, central alpha-2-adrenergic receptor agonists and other centrally acting antihypertensive drugs, aldosterone receptor antagonists, vasopeptidase inhibitors, NEP inhibitors, prostanoids, PDE5 inhibitors, nitrosylated compounds, oral nitrates and renin inhibitors, or combinations of agents from one or more than one such class.
  • agents of any class listed hereinabove including diuretics, ACE inhibitors, angiotensin II receptor blockers, beta-adrenergic receptor blockers, calcium channel blockers, direct vasodilators, alpha-1-adrenergic receptor block
  • the adjunctive or combination therapy can comprise administration of at least one diuretic and at least two antihypertensives selected from at least two of (a) ACE inhibitors and angiotensin II receptor blockers, (b) beta-adrenergic receptor blockers and (c) calcium channel blockers.
  • Illustratively antihypertensives for use in the method of the present embodiment can be selected from chlorothiazide, chlorthalidone, hydrochlorothiazide, indapamide, metalazone, polythiazide, bumetanide, furosemide, torsemide, benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, candesartan, eprosartan, irbesartan, losartan, olmesartan, tasosartan, telmisartan, valsartan, acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, labetalol, metoprolol, nadolol, penbutolo
  • a still further embodiment of the present invention provides a therapeutic combination comprising a selective ET A receptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ET A receptor antagonist.
  • a therapeutic combination comprising a selective ET A receptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ET A receptor antagonist.
  • Such a combination can have utility in a number of situations, not limited to methods described herein.
  • a combination of this embodiment can be especially useful for treating a complex of comorbidities in an elderly diabetic human subject as described above.
  • the selective ET A receptor antagonist and the at least one antidiabetic, anti-obesity or antidyslipidemic agent can be present in the combination in two or more separate dosage forms, permitting administration at the same or different times.
  • Such separate dosage forms can be formulated with one or more pharmaceutically acceptable excipients for administration via the same or different routes.
  • all agents in the combination are formulated for oral administration; in an even more particular embodiment all agents are formulated for once-daily oral administration and can be administered at the same time each day.
  • a treatment regimen includes administration of a plurality of drugs, as in the present instance, there are great benefits in convenience and compliance in standardizing route, frequency and timing of administration in this way.
  • separate dosage forms can optionally be co-packaged, for example in a single container or in a plurality of containers within a single outer package, or co-presented in separate packaging, for example as a kit comprising, in separate containers, a selective ET A receptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent.
  • the kit can optionally comprise separate labeling information for each agent, or a single product label having information on the therapeutic combination as a whole.
  • the selective ET A receptor antagonist and the at least one antidiabetic, anti-obesity or antidyslipidemic agent are separately packaged and available for sale independently of one another, but are co-marketed or co-promoted for use according to the invention.
  • the separate dosage forms can also be presented to a patient separately and independently, for use according to the invention.
  • the selective ET A receptor antagonist and the at least one antidiabetic, anti-obesity or antidyslipidemic agent are coformulated with one or more pharmaceutically acceptable excipients in a single pharmaceutical composition as a fixed-dose combination.
  • a pharmaceutical composition comprising the selective ET A receptor antagonist, the at least one antidiabetic, anti-obesity or antidyslipidemic agent, and one or more pharmaceutically acceptable excipients is itself a still further embodiment of the present invention.
  • the selective ET A receptor antagonist can illustratively be selected from those mentioned hereinabove.
  • the selective ET A receptor antagonist comprises darusentan, for example in a dosage amount as set forth hereinabove.
  • the combination or composition can comprise at least one antidiabetic, for example selected from alpha-glucosidase inhibitors, biguanides, exendins, hormones and analogs thereof, meglitinides, sulfonylurea derivatives and thiazolidinediones.
  • the selective ET A receptor antagonist comprises darusentan and the at least one antidiabetic is selected from acarbose, exenatide, glimepiride, insulins, metformin, nateglinide, pioglitazone, pramlintide, rosiglitazone and combinations thereof.
  • the combination or composition can comprise at least one anti-obesity agent, for example selected from anorexics, CB1 receptor blockers and lipase inhibitors.
  • the selective ET A receptor antagonist comprises darusentan and the at least one anti-obesity agent is selected from benzphetamine, methamphetamine, orlistat, phendimetrazine, phentermine, rimonabant, sibutramine and combinations thereof.
  • the combination or composition can comprise at least one antidyslipidemic, for example selected from bile acid sequestrants, cholesterol absorption inhibitors, fibrates, HMG CoA reductase inhibitors, nicotinic acid derivatives, and thyroid hormones and analogs thereof.
  • the selective ET A receptor antagonist comprises darusentan and the at least one antidyslipidemic is selected from atorvastatin, colesevelam, ezetimibe, fenofibrate, fluvastatin, lovastatin, niacin, rosuvastatin, simvastatin and combinations thereof.
  • the combination or composition can comprise a selective ET A receptor antagonist such as darusentan, a cholesterol absorption inhibitor such as ezetimibe, and an HMG CoA reductase inhibitor (statin) such as atorvastatin, fluvastatin, lovastatin, rosuvastatin or simvastatin.
  • a selective ET A receptor antagonist such as darusentan
  • a cholesterol absorption inhibitor such as ezetimibe
  • an HMG CoA reductase inhibitor such as atorvastatin, fluvastatin, lovastatin, rosuvastatin or simvastatin.
  • the combination or composition comprises, in one embodiment, a selective ET A receptor antagonist, at least one antidiabetic and at least one anti-obesity agent.
  • the combination or composition comprises, in another embodiment, a selective ET A receptor antagonist, at least one antidiabetic and at least one antidyslipidemic.
  • the combination or composition comprises, in yet another embodiment, a selective ET A receptor antagonist, at least one anti-obesity agent and at least one antidyslipidemic.
  • the combination or composition comprises, in a still further embodiment, a selective ET A receptor antagonist, at least one antidiabetic, at least one anti-obesity agent and at least one antidyslipidemic.
  • the combination or composition optionally further comprises at least one antihypertensive.
  • the at least one antihypertensive can comprise, for example, one or more agents of any class listed hereinabove or a combination of agents from more than one such class.
  • An illustrative combination or composition of the invention comprises:
  • the primary objective of this study was to assess the tolerability and safety profile of three-week oral applications of different doses of darusentan on top of established standard medicinal treatments in patients suffering from advanced chronic congestive heart failure NYHA functional class III. Secondary objective was the assessment of the short-tern effects of three-week darusentan treatment on hemodynamic parameters by means of SWAN GANZ floating catheterization and thermodilution.
  • double-blind treatment was started for a period of three weeks, followed by a one-week double-blind follow-up period.
  • PCWP pulmonary capillary wedge pressure
  • CI cardiac index
  • Test product dose, mode of administration and duration of treatment
  • Tablets containing 30mg, 100mg or 300mg darusentan Tablets containing 30mg, 100mg or 300mg darusentan.
  • Efficacy was analyzed primarily according to the intention-to-treat principle. Continuous data were described by statistical characteristics (n, mean, standard deviation, minimum, 1 st quartile, median, 3 rd quartile, maximum, number of missing values) for each time point, as well as for changes from baseline. For categorical data and adverse events, frequency and percentage were given. For the two primary efficacy parameters CI (l/min/m 2 ) and PCWP (mmHg), analysis-of-covariance models were calculated.
  • blood glucose levels (mg/dl or mmol/l) were determined at patient visits. Only fasting blood glucose levels are shown below. "N/A” is used where either blood glucose level was not examined or the laboratory test was performed when the patient was not fasting.
  • SBP systolic blood pressure
  • DBP diastolic blood pressure
  • CKD chronic kidney disease
  • the following is the protocol for a phase 3 randomized, double-blind, placebo-controlled, multi-center, parallel group study to evaluate the efficacy and safety of fixed doses of darusentan in subjects with resistant systolic hypertension receiving combination therapy with three or more antihypertensive drugs, including a diuretic.
  • Eligible subjects will include men and women, 35-80 years old, treated with full doses of three or more antihypertensive drugs, including a diuretic, with RHTN as defined by contemporary clinical guidelines for the treatment of hypertension [1,2].
  • Subjects with diabetes and/or CKD must have a SBP ⁇ 130 mmHg at Screening to be eligible for study entry. All other subjects must have a SBP of ⁇ 140 mmHg.
  • SBP at Screening must be ⁇ 180 mmHg for all subjects.
  • a BMI of 20 to 43 kg/m 2 or an upper arm circumference ⁇ 42 cm, and an eGFR ⁇ 30 mL/min/1.73 m 2 at Screening are also required.
  • Subject eligibility will be reassessed at the initiation of the 2-week single-blind Placebo Run-in Period and at the Randomization Visit (see Study Schematic), and only those subjects who continue to meet inclusion/exclusion criteria at these visits will be randomized into the study.
  • SBP and DBP measured at the Placebo Run-in Visit and at the Randomization Visit must be within 20 mmHg and 10 mmHg, respectively, of the values recorded at Screening in order for the subject to be eligible for randomization
  • Diabetic subjects must have a documented diagnosis of Type 2 diabetes prior to Screening, and all screened subjects will be evaluated for the presence of CKD according to the following definition: (i) reduced excretory function with an eGFR ⁇ 60 mL/min/1.73 m 2 and/or (ii) the presence of albuminuria in a spot urine sample (>200 mg/g [22.60 mg/mmol] creatinine).
  • Antihypertensive therapy must include:
  • antihypertensive drugs administered should be consistent with current treatment guidelines [1,2].
  • common multi-drug therapy may include a thiazide diuretic, an ACEI or an ARB, and a CCB.
  • Subjects may be on more than 3 antihypertensive drugs at entry as long as the minimum requirements described above are met.
  • hydrochlorothiazide HCTZ
  • hydrochlorothiazide HCTZ
  • a loop diuretic may be substituted for the thiazide diuretic in subjects with CKD or a documented contraindication/intolerance to treatment with a thiazide.
  • a potassium-sparing diuretic alone e.g., triamterene
  • the dose of each antihypertensive medication that the subject is receiving will be documented at Screening, and monitored throughout study participation.
  • the dose of each concomitant antihypertensive medication will be classified at study entry according to the following criteria:
  • the primary objective of this study is to determine if darusentan is effective in reducing SBP and DBP in subjects with RHTN, despite treatment with full doses of three or more antihypertensive drugs, including a diuretic.
  • the study will consist of three periods: Screening, Placebo Run-in, and Treatment. Screening assessments and evaluations may be conducted over a period of not more than 2 weeks. Following Screening, all eligible subjects will undergo a single-blind, Placebo Run-in of 2 weeks duration to ensure that blood pressure remains stable and continues to meet eligibility criteria for randomization. Subjects who continue to meet eligibility criteria following the 2-week Placebo Run-in Period will be randomized to one of four treatment groups (50, 100, or 300 mg of darusentan or placebo po qd), stratified by co-morbidity status (i.e., presence of diabetes and/or CKD versus the absence of these conditions) and race (i.e., Black versus non-Black).
  • Treatment will consist of three periods: Screening, Placebo Run-in, and Treatment. Screening assessments and evaluations may be conducted over a period of not more than 2 weeks. Following Screening, all eligible subjects will undergo a single-blind, Placebo Run-in of 2 weeks duration to ensure that blood pressure remains
  • Subjects randomized to placebo or 50 mg darusentan will receive their randomized dose of study drug throughout the 14-week Treatment Period. Subjects randomized to 100 or 300 mg darusentan will be initiated on 50 mg for 2 weeks and will subsequently undergo up-titration to the next higher dose of darusentan every 2 weeks until the randomized dose is achieved (see Figure 1 ). If a subject experiences a severe study drug-related AE during the Treatment Period, the subject's study drug dose may be reduced, according to investigator discretion. The choice to reduce the study drug dose may be made only once during the Treatment Period, and the change must be implemented prior to or at the Week 6 Visit. Once a subject's study drug dose has been down-titrated, it may not be subsequently increased.
  • Subjects requiring down-titration of study drug after study Week 6 must discontinue treatment with study drug; however, the subject should remain in study through the end of the Treatment Period (i.e., Week 14). Study drug assignments will remain double-blinded throughout the Treatment Period. All subjects will receive a fixed dose of study drug for a minimum of 8 weeks prior to the evaluation of study endpoints at the Week 14 Visit.
  • Adjustments to the number or dosage of concomitant antihypertensive medications will not be permitted at any time during the study. However, if a subject develops signs or symptoms of fluid retention during the Treatment Period, manifested as peripheral edema and/or clinically significant weight gain between study visits that in the opinion of the investigator requires immediate treatment, the subject's diuretic therapy may be adjusted according to investigator discretion. It is recommended that a loop diuretic be added, or the dose increased for subjects already receiving a loop diuretic, prior to adjusting concomitant thiazide diuretic therapy. All changes will be documented in detail in the subject's case report form (CRF). Adjustment of diuretics will not be allowed within 2 weeks of the primary endpoint assessment.
  • CRF case report form
  • Subjects who complete participation in the study through the Week 14 Visit, on or off study drug, will have the option to participate in a long-term safety extension study, with the exception of subjects who discontinue study drug due to a study drug-related AE.
  • Subjects who discontinue treatment with study drug prior to the end of the Treatment Period due to a study drug-related AE will not be eligible to participate in the long-term safety extension study.
  • Subjects who do not participate in the long-term safety extension study will discontinue treatment with study drug at the Week 14 Visit, and will return to the clinic for two safety visits prior to concluding study participation. Maximum placebo exposure in this study will be 16 weeks.
  • ALT serum alanine aminotransferase
  • AST aspartate aminotransferase
  • GTT gamma glutamyl aminotransferase
  • the co-primary endpoints are the change from baseline to Week 14 in trough sitting SBP and trough sitting DBP, as measured by sphygmomanometry.
  • Adjustment for multiple comparisons for the primary endpoints of change in SBP and DBP will use the fallback method.
  • SBP will be compared between the 300 mg dose and placebo at the nominal alpha level of 0.04. If this is significant, DBP will be compared between the 300 mg dose and placebo at the nominal level of 0.04. From this point, the fixed sequence procedure will be followed, requiring significance on an endpoint before allowing testing of the following endpoint, and testing all comparisons at the same level. If the 300 mg dose was significant at the 0.04 level for both SBP and DBP, the tests will be reported at the 0.05 level; otherwise the tests will be reported at the 0.01 level. These comparisons will be, in order, the 100 mg dose compared to placebo for SBP then DBP, and the 50 mg dose compared to placebo for SBP and then DBP. Continuous secondary endpoints will be handled analogously.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP12182366A 2007-08-22 2008-08-22 Therapie für Diabeteskomplikationen Withdrawn EP2545920A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95730007P 2007-08-22 2007-08-22
EP08798489A EP2190433A2 (de) 2007-08-22 2008-08-22 Therapie für diabeteskomplikationen

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP08798489.4 Division 2008-08-22

Publications (1)

Publication Number Publication Date
EP2545920A1 true EP2545920A1 (de) 2013-01-16

Family

ID=40220116

Family Applications (2)

Application Number Title Priority Date Filing Date
EP12182366A Withdrawn EP2545920A1 (de) 2007-08-22 2008-08-22 Therapie für Diabeteskomplikationen
EP08798489A Withdrawn EP2190433A2 (de) 2007-08-22 2008-08-22 Therapie für diabeteskomplikationen

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP08798489A Withdrawn EP2190433A2 (de) 2007-08-22 2008-08-22 Therapie für diabeteskomplikationen

Country Status (5)

Country Link
US (5) US20090054473A1 (de)
EP (2) EP2545920A1 (de)
JP (5) JP2010536880A (de)
CA (2) CA2697057A1 (de)
WO (1) WO2009026517A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070196510A1 (en) * 2006-02-17 2007-08-23 Gerber Michael J Method for treating resistant hypertension
JP2010535210A (ja) * 2007-07-31 2010-11-18 ギリード・コロラド・インコーポレーテッド アンブリセンタンの代謝産物および誘導体
EP2545920A1 (de) * 2007-08-22 2013-01-16 Abbott GmbH & Co. KG Therapie für Diabeteskomplikationen
CN101632672B (zh) * 2008-07-24 2011-01-12 鲁南制药集团股份有限公司 一种用于治疗高血压的复方药物组合物
ES2562957T3 (es) * 2009-04-30 2016-03-09 Midwestern University Método y composición para el tratamiento de la cetoacidosis diabética
US9255931B2 (en) * 2010-06-24 2016-02-09 Morehouse School Of Medicine Method and compositions for the treatment and detection of endothelin-1 related kidney diseases
EP2727587A1 (de) * 2012-10-30 2014-05-07 Pharnext Zusammensetzungen, Verfahren und Verwendung zur Behandlung von Diabetes und zugehöriger Erkrankungen durch Regelung des Blutzuckerwerts
EP2991680A1 (de) 2013-04-30 2016-03-09 AbbVie Inc. Verfahren zur verbesserung von lipidprofilen mittels atrasentan
JO3624B1 (ar) * 2014-05-08 2020-08-27 Lilly Co Eli تركيبات إنسولين سريعة المفعول
CN107106522A (zh) * 2014-11-07 2017-08-29 艾伯维公司 使用液体潴留的预测因子治疗ckd的方法
JO3749B1 (ar) * 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
US10369156B2 (en) * 2016-11-15 2019-08-06 The George Institute for Global Health Compositions for the treatment of hypertension
ES2940316T3 (es) 2017-01-25 2023-05-05 The George Inst For Global Health Composiciones para el tratamiento de la hipertensión
KR102568472B1 (ko) 2017-02-27 2023-08-18 이도르시아 파마슈티컬스 리미티드 엔도텔린 관련 질환의 치료를 위한 4-피리미딘술파미드 유도체와 활성 성분의 조합물
US20190260657A1 (en) * 2018-02-21 2019-08-22 Cisco Technology, Inc. In-band performance loss measurement in ipv6/srv6 software defined networks
JP7458032B2 (ja) * 2018-05-03 2024-03-29 ミッドウェスタン ユニバーシティ 出血およびセンタキンによる蘇生後のエンドセリン受容体の変化
WO2019226417A1 (en) * 2018-05-23 2019-11-28 University Of Miami Methods of treating renal disease associated with chronic kidney disease such as alport syndrome
US20200030296A1 (en) * 2018-07-26 2020-01-30 The George Institute for Global Health Compositions for the treatment of hypertension
CA3158767A1 (en) 2019-10-30 2021-05-06 Perfuse Therapeutics, Inc. Treatment of ocular diseases using endothelin receptor antagonists
BR112022012075A2 (pt) 2019-12-17 2022-08-30 Chinook Therapeutics Inc Métodos para tratar nefropatia por iga com atrasentan
JP2023541766A (ja) 2020-07-10 2023-10-04 アストラゼネカ・アクチエボラーグ 慢性腎疾患の治療のためのジボテンタン及びダパグリフロジンの組み合わせ
KR20240004643A (ko) 2021-04-30 2024-01-11 퍼퓨즈 세라퓨틱스, 인크. 안구 질환의 치료를 위한 제약 조성물 및 유리체내 약물 전달 시스템
CN116804048A (zh) * 2023-02-24 2023-09-26 中国农业大学 豌豆白蛋白分离肽、组合物及其用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19743140A1 (de) 1997-09-30 1999-04-01 Knoll Ag Pharmazeutische Kombinationspräparate
DE19743142A1 (de) 1997-09-30 1999-04-01 Knoll Ag Pharmazeutische Kombinationspräparate
DE19744799A1 (de) 1997-10-10 1999-04-15 Knoll Ag Pharmazeutische Kombinationspräparate
US6197780B1 (en) 1997-12-05 2001-03-06 Knoll Aktiengesellschaft Method for combating obesity
US6329384B1 (en) 1997-09-26 2001-12-11 Abbott Laboratories Endothelin antagonist and renin-angiotensin system inhibitor as a combined preparation
US6352992B1 (en) 1997-09-30 2002-03-05 Abbott Laboratories Endothelin antagonist and beta receptor blocking agent as combined preparations
US20040186083A1 (en) * 2003-03-18 2004-09-23 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an endothelin receptor antagonist and/or endothelin converting enzyme inhibitor

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO942396L (no) * 1993-06-24 1994-12-27 Takeda Chemical Industries Ltd Preparat med vedvarende frigiving av anti-endotelin substans
CZ285522B6 (cs) * 1993-06-24 1999-08-11 Eli Lilly And Company Farmaceutický prostředek pro snížení koncentrace glukosy v krvi
US5767144A (en) * 1994-08-19 1998-06-16 Abbott Laboratories Endothelin antagonists
US7208517B1 (en) * 1994-08-19 2007-04-24 Abbott Labortories Endothelin antagonists
US6946481B1 (en) * 1994-08-19 2005-09-20 Abbott Laboratories Endothelin antagonists
US6162927A (en) * 1994-08-19 2000-12-19 Abbott Laboratories Endothelin antagonists
US7365093B2 (en) * 1994-08-19 2008-04-29 Abbott Laboratories Endothelin antagonists
KR100483222B1 (ko) 1994-08-19 2005-04-15 아보트 러보러터리즈 엔도텔린 길항제
CN1091768C (zh) 1996-02-13 2002-10-02 艾博特公司 作为内皮素拮抗剂的新的苯并-1,3-间二氧杂环戊烯基和苯并呋喃基取代的吡咯烷衍生物
US6420412B2 (en) * 1996-03-29 2002-07-16 Smithkline Beecham Corporation Eprosartan dihydate and a process for its production and formulation
US6121416A (en) * 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
JP2001512119A (ja) 1997-08-04 2001-08-21 アボット・ラボラトリーズ エンドセリン拮抗薬
US7445792B2 (en) * 2003-03-10 2008-11-04 Abbott Laboratories Medical device having a hydration inhibitor
US8257725B2 (en) * 1997-09-26 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
EP1114022A1 (de) 1998-09-14 2001-07-11 Abbott Laboratories Verfahren zur herstellung von stereoselektiven nitro-verbindungen
US8257724B2 (en) * 1998-09-24 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
US6238708B1 (en) * 1999-02-23 2001-05-29 The Iams Company Composition and process for controlling glucose metabolism in companion animals by dietary starch
US6559188B1 (en) * 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
TWI306760B (en) 2000-08-07 2009-03-01 Abbott Lab Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same
US20020055457A1 (en) * 2000-08-07 2002-05-09 Janus Todd J. Methods of treating cancer and the pain associated therewith using endothelin antagonists
WO2002017912A1 (en) 2000-08-31 2002-03-07 Abbott Laboratories Endothelin antagonists
US20030022811A1 (en) * 2001-04-11 2003-01-30 Amitabh Singh Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
WO2002085351A1 (en) 2001-04-11 2002-10-31 Abbott Laboratories Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
US20030092757A1 (en) * 2001-04-11 2003-05-15 Amitabh Singh Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
JP4263095B2 (ja) * 2001-09-21 2009-05-13 ノバルティス アクチエンゲゼルシャフト Ａｃｅおよびｎｅｐの両阻害剤としてのピラン誘導体
CA2479254A1 (en) * 2002-03-22 2003-10-02 Kissei Pharmaceutical Co., Ltd. Preventive or therapeutic agent for renal disease
GB0212412D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
CN101884789A (zh) * 2004-02-11 2010-11-17 法布罗根股份有限公司 Ctgf作为糖尿病肾病的治疗靶点
SG153831A1 (en) * 2004-03-17 2009-07-29 Novartis Ag Use of renin inhibitors in therapy
CA2559747C (en) * 2004-03-19 2013-12-31 Abbott Laboratories Multiple drug delivery from a balloon and a prosthesis
WO2006034234A1 (en) 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form 3 of atrasentan hydrochloride
WO2006034094A1 (en) 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form 1 of atrasentan hxdrochloride
MX2007003158A (es) * 2004-09-17 2007-05-15 Abbott Lab Forma cristalina 2 del clorhidrato de atrasentan.
WO2006034085A1 (en) 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form of atrasentan hydrochloride
AU2006250354A1 (en) * 2005-05-23 2006-11-30 Japan Tobacco Inc. Pyrazole compound and therapeutic agent for diabetes comprising the same
US20080132710A1 (en) * 2006-12-04 2008-06-05 Abbott Laboratories Atrasentan hydrochloride crystalline form 2
EP2545920A1 (de) * 2007-08-22 2013-01-16 Abbott GmbH & Co. KG Therapie für Diabeteskomplikationen
US20100184026A1 (en) * 2009-01-22 2010-07-22 Abbott Laboratories Companion Diagnostic Assays For Endothelin Receptor Antagonists

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6329384B1 (en) 1997-09-26 2001-12-11 Abbott Laboratories Endothelin antagonist and renin-angiotensin system inhibitor as a combined preparation
DE19743140A1 (de) 1997-09-30 1999-04-01 Knoll Ag Pharmazeutische Kombinationspräparate
DE19743142A1 (de) 1997-09-30 1999-04-01 Knoll Ag Pharmazeutische Kombinationspräparate
US6352992B1 (en) 1997-09-30 2002-03-05 Abbott Laboratories Endothelin antagonist and beta receptor blocking agent as combined preparations
DE19744799A1 (de) 1997-10-10 1999-04-15 Knoll Ag Pharmazeutische Kombinationspräparate
US6197780B1 (en) 1997-12-05 2001-03-06 Knoll Aktiengesellschaft Method for combating obesity
US20040186083A1 (en) * 2003-03-18 2004-09-23 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an endothelin receptor antagonist and/or endothelin converting enzyme inhibitor
WO2004082637A2 (en) 2003-03-18 2004-09-30 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an endothelin receptor antagonist and/or endothelin converting enzyme inhibitor

Non-Patent Citations (26)

* Cited by examiner, † Cited by third party
Title
"2003 European Society of Hypertension-European Society of Cardiology Guidelines for the Management of Arterial Hypertension", J HYPERTENS, vol. 21, no. 6, 2003, pages 1011 - 1053
"Diabetes Care", vol. 27, 2004, AMERICAN DIABETES ASSOCIATION, pages: S79 - S83
BALSIGER BRUNO ET AL: "Endothelin A-receptor blockade in experimental diabetes improves glucose balance and gastrointestinal function", CLINICAL SCIENCE (LONDON), vol. 103, no. Suppl. 48, August 2002 (2002-08-01), pages 430S - 433S, XP002511104, ISSN: 0143-5221 *
BALSIGER ET AL., CLIN. SCI., vol. 103, no. 48, 2002, pages 430S - 433S
BATTISTINI ET AL., EXP. BIOL. MED., vol. 231, 2006, pages 653 - 695
BERTHIAUME ET AL., METAB, CLIN. EXP., vol. 54, 2005, pages 735 - 740
BERTHIAUME ET AL: "Endothelin antagonism improves hepatic insulin sensitivity associated with insulin signaling in Zucker fatty rats", METABOLISM, CLINICAL AND EXPERIMENTAL, W.B. SAUNDERS CO., PHILADELPHIA, PA, US, vol. 54, no. 11, 1 November 2005 (2005-11-01), pages 1515 - 1523, XP005189689, ISSN: 0026-0495, DOI: 10.1016/J.METABOL.2005.05.019 *
CHOBANIAN AV; BAKRIS GL; BLACK HR; CUSHMAN WC; GREEN LA; IZZO JL, JR. ET AL.: "Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure", HYPERTENSION, vol. 42, no. 6, 2003, pages 1206 - 1252
CHOBANIAN, HYPERTENSION, vol. 42, 2003, pages 1206 - 1252
DHIEN ET AL., J. PHARMACOL. EXP. THERAP., vol. 293, 2000, pages 351 - 359
FERRI ET AL., EXP. CLIN. ENDOCRINOL. DIABETES, vol. 105, 1997, pages 38 - 40
FUKAMI K ET AL: "Novel therapeutic targets for diabetic nephropathy", ENDOCRINE, METABOLIC & IMMUNE DISORDERS - DRUG TARGETS, BENTHAM SCIENCE PUBLISHERS LTD, BUSSUM, NL, vol. 7, no. 2, 1 January 2007 (2007-01-01), pages 83 - 92, XP009110527, ISSN: 1871-5303 *
HOCHER B ET AL: "Effects of endothelin receptor antagonists on the progression of diabetic nephropathy", NEPHRON,, vol. 87, no. 2, 1 February 2001 (2001-02-01), pages 161 - 169, XP009110722, ISSN: 0028-2766 *
HOCHER ET AL., NEPHRON, vol. 87, 2001, pages 161 - 169
HOFMAN C ET AL: "Endothelin A antagonist LU-135252 and trandolapril in the treatment of the Cohen-Rosenthal diabetic hypertensive rat", BLOOD PRESSURE 2005 NO, vol. 14, no. 2, 2005, pages 114 - 119, XP009110942 *
J. HUMAN HYPERTENS., vol. 18, 2004, pages 139 - 185
J. HYPERTENS., vol. 21, 2003, pages 1011 - 1053
J. HYPERTENS., vol. 21, 2003, pages 1983 - 1992
LIP, IDRUGS, vol. 4, no. 11, 2001, pages 1284 - 1292
NAKOV ET AL., AM. J. HYPERTENS., vol. 15, 2002, pages 583 - 589
RIECHERS ET AL., J. MED. CHEM., vol. 39, 1996, pages 2123 - 2128
SHAW ET AL., EXP. BIOL. MED., vol. 231, 2006, pages 1101 - 1105
SHAW; BODEN, CURRENT VASCULAR PHARMACOLOGY, vol. 3, 2005, pages 359 - 363
SOROKIN; KOHAN, AM. J. PHYSIOL. RENAL PHYSIOL, vol. 285, 2003, pages F579 - F589
TAKAHASHI ET AL., DIABETOLOGIA, vol. 33, 1990, pages 306 - 310
WENZEL ET AL: "SPP301 Phase IIb Results in Diabetic Nephropathy Presented at ASN", 12 November 2005 (2005-11-12), XP002511103, Retrieved from the Internet <URL:http://www.redorbit.com/news/health/303255/spp301_phase_iib_results_in_diabetic_nephropathy_presented_at_asn/index.html?source=r_health> [retrieved on 20090114] *

Also Published As

Publication number Publication date
US20130178424A1 (en) 2013-07-11
CA2904447A1 (en) 2009-02-26
CA2904447C (en) 2017-01-03
WO2009026517A3 (en) 2009-05-28
US8865650B2 (en) 2014-10-21
CA2697057A1 (en) 2009-02-26
US8623819B2 (en) 2014-01-07
EP2190433A2 (de) 2010-06-02
US20170079978A1 (en) 2017-03-23
JP2015028062A (ja) 2015-02-12
JP2014001234A (ja) 2014-01-09
JP2010536880A (ja) 2010-12-02
US20150051234A1 (en) 2015-02-19
WO2009026517A2 (en) 2009-02-26
JP2016053057A (ja) 2016-04-14
JP2017145251A (ja) 2017-08-24
US9592231B2 (en) 2017-03-14
US20140073574A1 (en) 2014-03-13
US20090054473A1 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
US9592231B2 (en) Therapy for complications of diabetes
RU2310443C2 (ru) Синергетические композиции, которые содержат ингибитор ренина, предназначенные для лечения сердечно-сосудистых заболеваний
US20070196510A1 (en) Method for treating resistant hypertension
JP6337170B2 (ja) ネコの全身性疾患の予防又は治療の為のアンジオテンシンｉｉ受容体アンタゴニスト
JP2005533023A5 (de)
US20070293552A1 (en) Antihypertensive therapy method
US20090221549A1 (en) Antihypertensive therapy
WO2006130901A1 (en) Control of metabolic abnormalities
JP2009256209A (ja) 降圧療法
JP2018521077A (ja) 糖尿病性腎症を治療するためのｐｄｅ４阻害剤

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 2190433

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ABBVIE DEUTSCHLAND GMBH & CO KG

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1180956

Country of ref document: HK

17P Request for examination filed

Effective date: 20131112

RBV Designated contracting states (corrected)

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20151211

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180206

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1180956

Country of ref document: HK